Abiraterone and Increased Survival in Metastatic Prostate Cancer - de Bono, Johann S; Logothetis, Christopher J; Molina, Arturo; Fizazi, Karim; North, Scott; Chu, Luis; Chi, Kim N; Jones, Robert J; Goodman, Oscar B; Saad, Fred; Staffurth, John N; Mainwaring, Paul; et al. (The New England journal of medicine, 2011)
Keywords: Acetic acid; Aged; Androgen Antagonists - adverse effects; Androgen Antagonists - therapeutic use; Androgens; Androgens - biosynthesis; Androstenes; Androstenols - adverse effects; Androstenols - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Biosynthesis; Biotechnology; Cancer therapies; Castration; Chemotherapy; Disease Progression; Double-Blind Method; Fatigue - chemically induced; Fees & charges; General aspects; Gynecology. Andrology. Obstetrics; Humans; Hypertension; Hypokalemia; Kaplan-Meier Estimate; Laboratories; Male; Male genital diseases; Medical research; Medical sciences; Metastases; Middle Aged; Neoplasm Metastasis; Nephrology. Urinary tract diseases; Oncology; Pain; Patients; Prednisone; Prednisone - therapeutic use; Prostate cancer; Prostate-specific antigen; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - mortality; Prostatic Neoplasms - pathology; Steroid 17-alpha-Hydroxylase - antagonists & inhibitors; Survival; Survival Analysis; Treatment Outcome; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Urinary system disease; Prostate disease; Abiraterone; Antiandrogen; Antihormone; Malignant tumor; Metastasis; Survival; Medicine; Advanced stage; Metastatic; Male genital diseases; Prostate cancer; Cancer